Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.21.1
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 42 Months Ended 75 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]          
Prior period performance obligation revenue recognized $ 28,000,000.0 $ 8,900,000      
Overpayment reimbursement liability 11,800,000   $ 11,800,000 $ 11,800,000 $ 14,900,000
Revenue recognized 790,000   $ 0    
Total revenues 545,165,000 211,466,000      
Rayaldee          
Disaggregation of Revenue [Line Items]          
Revenue recognized 5,800,000 9,900,000      
Total revenues 15,645,000        
Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues 4,269,000 9,553,000      
Products | Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues 3,000,000        
Pfizer | Products          
Disaggregation of Revenue [Line Items]          
Revenue recognized       $ 0  
Pfizer | Products | Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues $ 2,800,000 $ 8,700,000